Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04982952 · ClinicalTrials.gov registry record · NA

Contingency Management for Smoking Cessation

A NA study of Smoking Cessation and Smoking, Tobacco, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
83
Enrollment target
2
Study locations

NCT04982952: Completed NA study of Smoking Cessation and Smoking, Tobacco, sponsored by University of California, San Francisco.

NCT04982952 is a NA study of Smoking Cessation and Smoking, Tobacco that has completed, run by University of California, San Francisco. The registered enrollment target is 83 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04982952, a NA study of Smoking Cessation and Smoking, Tobacco, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
83 participants
Enrollment target
2
Study locations

Study Summary

The prevalence of smoking in the homeless population (70%) is over 4 times that of the general population (15%). Homeless adults have not experienced similar declines in tobacco use as the general population has over the past three decades. Homeless adults are interested in smoking cessation and make quit attempts, but are less successful in quitting smoking than the general population. Trials of group behavioral counseling and pharmacotherapy for smoking cessation have not led to substantial long-term abstinence (i.e., abstinence for 6 months or more), suggesting that these interventions alone are insufficient to improve quit rates among homeless adults. Many homeless adults seek health care in safety net clinics; these clinics could bring cessation interventions to scale. Contingency management is a powerful behavior change intervention that reinforces positive health behaviors through the provision of modest incentives (e.g., cash). In this pilot randomized controlled trial, the investigator will test the feasibility and acceptability of a contingency management intervention that provides incentives for smoking cessation for people experiencing homelessness.

Primary Outcome

The proportion of participants who achieve biochemically-verified 7-day point prevalence abstinence defined as participants (1) reporting not smoking a single cigarette in the past seven days, not even a puff; (2) having carbon monoxide (CO) levels \<=5 parts per million (ppm), and (3) urinary anatabine/anabasine assay levels \< 2 nanograms per milliliter (ng/ml).

Interventions

  • BEHAVIORAL Contingency Management - Increasing
  • BEHAVIORAL Fixed payments

Study Locations (2)

California

  • The Richard H. Fine's People's Clinic - San Francisco
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2021-11-09
Est. Completion 2024-06-30
Phase NA

What the finished NCT04982952 record still lists

NCT04982952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Contingency Management - Increasing is the first listed.

NCT04982952 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04982952 about?

NCT04982952 is a clinical study titled "Contingency Management for Smoking Cessation". The prevalence of smoking in the homeless population (70%) is over 4 times that of the general population (15%). Homeless adults have not experienced similar declines in tobacco use as the general population has over the past three decades. Homeless adults are interested in smoking cessation and mak...

What is the current status of trial NCT04982952?

This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2021-11-09. Estimated completion is 2024-06-30.

What conditions does trial NCT04982952 study?

This clinical trial studies the following conditions: Smoking Cessation, Smoking, Tobacco, Smoking Reduction.

What interventions are being tested in trial NCT04982952?

The interventions under investigation include: Contingency Management - Increasing (BEHAVIORAL), Fixed payments (BEHAVIORAL).

Who is sponsoring clinical trial NCT04982952?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04982952 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04982952's enrollment target sits among peer trials

83 124th of 188 higher than 65 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04982952, the US trial registry maintained by the National Library of Medicine. NCT04982952 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.